Biocon Q2 Profit zooms 168% to ₹126 crore (YoY), driven by the acquisition of Viatris Biosimilars business and research services. The Revenue grew by 49% to ₹3,462 crore (YoY), and EBITDA grew by 68% to ₹900 crore. The gross R&D spending grew 10% YoY to Rs 278 crore in Q2FY24. Catch Sakshi Batra in conversation with Shreehas Tambe, CEO & Managing Director, Biocon Biologics discussing the earnings and further acquisition plans in the Emerging Markets.